Toronto, May 25- Geneseeq Technology Inc. is set to present four collaborative studies at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, scheduled to take place in Chicago from June 2nd to 6th. These studies, which will be presented both in-person and virtually, highlight significant findings related to various types of solid tumors.

Here are the key highlights from these studies:

  • Performance of cfDNA fragmentonics-based early detection models in gastric cancer and breast cancer populations. The findings shed light on the potential of this approach in improving early diagnosis and subsequent treatment outcomes.
  • Novel drug resistance mechanism in ROS1-rearranged non-small cell lung cancer patients. This research provides valuable insights into the development of targeted therapies and the management of treatment resistance in this subset of patients.
  • Comprehensive analysis of homologous recombination repair gene reversion mutations. By examining a large pan-cancer population, this study sheds light on the prevalence, clinical implications, and potential therapeutic implications of these mutations.

Abstracts of the studies to be presented: